ea0089c6 | Clinical – Chemo/SSA/Biologics | NANETS2022
Eads, MD Jennifer R.
, Das, MD Satya
, Li, MD Daneng
, Mohamed, MD Amr
, Tucci, MBS, CCRP Christopher
, Nanda, MS Shivani
, Kauh, MD, FACP John S.
, Kania, MD, MBA Marek K.
, Dasari, MD Arvind
Background: Surufatinib, an oral small molecule tyrosine kinase inhibitor, selectively inhibits vascular endothelial growth factor receptor 1, 2, and 3; fibroblast growth factor receptor 1; and colony-stimulating factor 1 receptor. Tislelizumab is a humanized immunoglobulin G4-variant anti-programmed cell death protein-1 monoclonal antibody. Combining surufatinib and tislelizumab may have synergistic effects, where inhibition of angiogenesis and stimulation of an immune respon...